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Abstract 
Background: Although coronavirus disease 2019 (COVID‑19) is primarily a respiratory illness, myocardial injury is 
increasingly reported and associated with adverse outcomes. However, the pathophysiology, extent of myocardial 
injury and clinical significance remains unclear.
Methods: COVID‑HEART is a UK, multicentre, prospective, observational, longitudinal cohort study of patients with 
confirmed COVID‑19 and elevated troponin (sex‑specific > 99th centile). Baseline assessment will be whilst recovering 
in‑hospital or recently discharged, and include cardiovascular magnetic resonance (CMR) imaging, quality of life (QoL) 
assessments, electrocardiogram (ECG), serum biomarkers and genetics. Assessment at 6‑months includes repeat CMR, 
QoL assessments and 6‑min walk test (6MWT). The CMR protocol includes cine imaging, T1/T2 mapping, aortic disten‑
sibility, late gadolinium enhancement (LGE), and adenosine stress myocardial perfusion imaging in selected patients. 
The main objectives of the study are to: (1) characterise the extent and nature of myocardial involvement in COVID‑19 
patients with an elevated troponin, (2) assess how cardiac involvement and clinical outcome associate with recog‑
nised risk factors for mortality (age, sex, ethnicity and comorbidities) and genetic factors, (3) evaluate if differences in 
myocardial recovery at 6 months are dependent on demographics, genetics and comorbidities, (4) understand the 
impact of recovery status at 6 months on patient‑reported QoL and functional capacity.
Discussion: COVID‑HEART will provide detailed characterisation of cardiac involvement, and its repair and recovery 
in relation to comorbidity, genetics, patient‑reported QoL measures and functional capacity.
Clinical Trial registration: ISRCTN 58667920. Registered 04 August 2020.
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Background
The coronavirus disease 2019 (COVID-19) severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) 
pandemic [1] was initially recognised as a primarily 
respiratory illness with a severe acute respiratory syn-
drome, but it is now known that it can affect multiple 
organs with a wide spectrum of disease severity [2, 3].
The direct cardiovascular impact of COVID-19 is 
three-fold. Firstly, underlying cardiovascular disease 
(CVD) can predispose patients to the infection and is 
associated with an increased illness severity. Secondly, 
COVID-19 may exacerbate underlying cardiovascu-
lar co-morbidities leading to symptom destabilisation 
and potentially acute admission to hospital. Thirdly, de 
novo cardiac complications of COVID-19 may occur 
[4], with SARS-CoV-2 infection being implicated in 
acute myocarditis, pericarditis, prothrombotic compli-
cations, left ventricular (LV) and/or right ventricular 
(RV) dysfunction, arrhythmia and ischaemic seque-
lae in the presence or absence of underlying coronary 
artery disease (CAD) [1, 4–6].
Multiple studies have demonstrated that myocardial 
injury, characterised by elevation in serum cardiac bio-
markers, is common in COVID-19. The prevalence of 
myocardial injury, however, is variably reported, with 
early studies quoting a prevalence of 8–12% in hospi-
talised patients, whilst more recent data suggest that 
it is possibly much higher [4, 7]. Subsequently, a larger 
multicentre study of 305 patients identified an elevated 
troponin in more than half of the hospitalised patients 
[8]. A recent German cohort study reported imaging 
evidence of myocardial injury defined by cardiovascu-
lar magnetic resonance (CMR) in over 70%, although 
whether this was pre-existing or consequence was 
unclear with single time-point imaging [9]. The under-
lying mechanism of cardiac injury and troponin eleva-
tion remains unclear, but there are several potential 
explanations. Troponin T release is commonly seen in 
critically ill patients because of oxygen supply–demand 
mismatch and cytokine release, acute heart failure, RV 
strain (secondary to pneumonia, hypoxia and increased 
pulmonary artery pressure) and acute arrhythmia 
[10–12]. Furthermore, the acute-phase response to 
severe coronavirus infection can lead to coagulopa-
thy and microvascular thrombosis, for example in the 
pulmonary and coronary circulations [13, 14]. Pre-
existing coronary risk factors, such as hypertension 
and diabetes also predispose patients with COVID-19 
to myocardial infarction in the acute setting, possibly 
implicating it as another potential disease mechanism 
[15]. On a cellular level, however, direct myocardial 
injury may occur due to viral angiotensin-converting 
enzyme-2 transmembrane receptor mediated damage, 
microvascular dysfunction or increased vessel wall per-
meability [16].
Troponin elevation in hospitalised COVID-19 patients 
is associated with higher morbidity and increased short-
term mortality [4, 8, 17–21], particularly in those who 
also have underlying CVD [16]. Those with CV comor-
bidities (diabetes, hypertension, heart failure or CAD/
peripheral artery disease) are heavily over-represented in 
both severe COVID-19 and mortality [22, 23].
An elevated troponin should prompt a search for cau-
sation, and particularly imaging, as structural abnor-
malities are likely to be found in this cohort and further 
predict adverse outcomes (Fig.  1) [4, 8, 17–20, 24]. In 
patients with an elevated troponin and non-obstructive 
coronary arteries, CMR can provide the diagnosis in 
up to 90% of cases [25], and   is the imaging modality of 
choice for diagnosis of acute myocarditis [26]. The diag-
nostic performance of the CMR-Lake Louise imaging cri-
teria to identify acute myocarditis has been reported to 
have an overall diagnostic accuracy of around 83% (sen-
sitivity 78–80% and specificity ~ 87–88%) [27, 28]. CMR 
can also identify persistent inflammation and the pres-
ence of fibrosis in patients recovered from COVID-19 
[9, 29], which may have long-term clinical implications. 
Furthermore, CMR is the reference standard method for 
assessing LV and RV pathology, whilst regional perfusion 
defects consistent with obstructive CAD can be accu-
rately identified using CMR perfusion [30].
Based on the  possibility  that myocardial injury may 
be relatively common in COVID-19 patients, and has 
been shown to be a marker of poor prognosis, further 
studies are required to clarify the pathophysiology of 
SARS-CoV-2 related myocardial injury. In particular, the 
nature of injury may suggest the need for therapeutic 
intervention, which may be specific (e.g. antithrombotic, 
anti-inflammatory), or non-specific e.g. heart failure 
treatment. Importantly, the nature and extent of myocar-
dial injury may also help risk stratify patients both acutely 
and chronically, and for this, multi-time-point imaging 
is required to separate out cause and effect. Finally, the 
underlying risk factors for myocardial involvement and 
the impact on long-term clinical outcomes need to be 
investigated.
Keywords: COVID‑19, Coronavirus, Cardiovascular magnetic resonance, Myocarditis, Myopericarditis, Myocardial 
infarction, myocardial injury, Myocardial inflammation, Myocardial repair, Cardiovascular disease
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Methods
Objectives
The primary objectives of COVID-HEART are, for a 
hospitalised-recovering patient population (or those 
recently discharged), to: (1) characterise the nature and 
extent of myocardial involvement in COVID-19 patients 
with an elevated troponin; (2) assess how cardiac involve-
ment and clinical outcome associate with recognised risk 
factors for mortality in COVID-19 (age, sex, ethnicity 
and comorbidities) and with genetic factors; (3) evalu-
ate if differences in myocardial recovery at 6-months are 
dependent on demographics, genetics and CVD comor-
bidities (diabetes, hypertension, heart failure and CAD/
peripheral vascular disease); (4) understand the impact of 
recovery status at 6-months on patient-reported quality 
of life (QoL) and functional capacity.
The secondary objectives include: (a) to examine 
whether there are characteristic electrocardiogram 
(ECG) findings specific for SARS-CoV-2 myocardi-
tis that are distinct from acute myocardial infarction 
which could minimise the requirement for invasive car-
diac catheterisation and, (b) to establish the nature and 
prevalence of myocardial ischaemia and microvascular 
dysfunction (coronary vascular sub-study).
Study design
A longitudinal, multicentre, observational cohort study 
of UK patients presenting with COVID-19 and elevated 
serum troponin, who are either recovering in hospital 



















Fig. 1 Electrocardiogram (ECG) and cardiovascular magnetic resonance (CMR) examples in troponin positive COVID‑19. Potential diagnoses 
include: no abnormalities detected, myocarditis, infarction, dual pathology and pericardial inflammation. First example shows a normal 12‑lead 
electrocardiogram (ECG) and a normal CMR study. Second example shows myocarditis, with anterolateral ST segment flattening. CMR shows 
normal function but patchy mid‑wall enhancement in the anterior and inferior wall (red arrows) with T2 map showing co‑localised oedema. 
The third example shows myocardial infarction with ECG anterolateral ST changes and thinning of left ventricular (LV) wall predominantly in the 
anterolateral segment on the short‑axis image (red asterisk); corresponding LGE image shows an ischaemic pattern transmural scar (red arrow); T1 
maps show elevated T1 values in the lateral wall. The fourth example shows a case of dual pathology due to myocarditis and infarction. The ECG 
shows hyperacute T‑waves in the anterolateral leads and the CMR study shows a short‑axis cine with increased signal intensity in the anterior/
anteroseptal segment (red asterisk). The two LGE images reveal an ischaemic scar in this area extending from subendocardium as well as an area of 
sub‑epicardial enhancement in the inferior wall consistent with myocarditis (red arrows). The last case presents pericardial inflammation. The ECG 
shows widespread concave ST‑segment elevation. The 4‑chamber cine is unremarkable, whereas the corresponding LGE images show pericardial 
enhancement (red arrows)
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Ethics and registration
Ethical approval for the COVID-HEART study has 
been granted by the UK National Research Ethics Ser-
vice (20/NW/0292). COVID-HEART is registered on 
the ’International Standard Randomised Controlled 
Trial’ registry (ISRCTN 5866,920) https:// doi. org/ 10. 
1186/ ISRCT N5866 7920.
Funding, sponsorship and prioritisation
COVID-HEART is funded by the National Institute for 
Health Research (NIHR) and UK Research and Innova-
tion (UKRI) COVID-19 Rapid Response Rolling Call 
(grant number COV0254), and sponsored by the Uni-
versity of Leeds, UK. The study has been endorsed by 
the British Society of Cardiovascular Magnetic Reso-
nance (BSCMR) Research Group, and nationally pri-
oritised, and received both BHF-NIHR Cardiovascular 
Partnership Flagship Status, and the NIHR Urgent 
Public Health Group identified it as an Urgent Public 
Health (UPH) study. Funding for the translation of the 
patient information leaflets into non-English languages 
was provided by the West Yorkshire and Humber Clini-
cal Research Network (CV070).
Study population
Inclusion criteria include—hospitalised-recovering 
patient population (age ≥ 18  years), or those recently 
discharged from hospital, with a diagnosis of COVID-
19 based upon either a pathology or radiology diagno-
sis, with cardiac biomarkers (troponin I or T) increased 
above the sex-specific upper reference limit of the local 
laboratory range. Exclusion criteria include being una-
ble or unwilling to consent, contraindication to CMR, 
pregnancy or breast-feeding.
Contemporary patient cohorts acting as control data 
will be acquired for comparative CMR analysis. These 
will be derived from ethically approved local research 
studies from the recruiting centres for COVID-
HEART using the same CMR scanners (vendor and 
field strength). As the patients in COVID-HEART are 
COVID( +) and Troponin( +), control populations will 
include:
1) A population matched for age and CVD risk factors, 
who have been hospitalised and are COVID( +) and 
Troponin(−) [e.g. Capturing MultiORgan Effects 
of COVID-19 (C-MORE) cohort, Oxford, UK; 
NCT04510025].
2) A population matched for age and CVD risk factors, 
who have tested COVID(−) and Troponin(−).
Setting
Recruitment will take place in 25 participating secondary 
or tertiary care hospitals across the UK, all of whom have 
access to well-established local CMR services.
Recruitment process and data collection
Screening will be performed at an individual hospital 
level, with participating hospitals cross-referencing all 
admissions with a positive COVID-19 status (pathology/
radiology diagnosis), with serum troponin results. This 
study will integrate two key aspects. Work package-1 will 
establish a national image repository for patients with 
COVID-19 who have CMR for clinical reasons. Work 
package-2 (objectives as outlined above) will use CMR to 
characterise the nature and extent of myocardial injury 
in a hospitalised but recovering patient population, who 
are serum biomarker (troponin) positive for myocardial 
damage.
The source data will include hospital records, National 
Health Service (NHS) health and social care records, 
clinical and office charts, laboratory and pharmacy 
records as well as digital images from radiology (chest 
X-ray/computed tomography/CMR) and cardiology 
(echocardiography/angiography/CMR). Patients in work 
package-1 who have a clinically indicated CMR and are 
troponin positive will be invited to join work package-2 
for a follow-up CMR scan and assessment at 6 months. 
Clinical follow up for vital status and cardiovascular 
events at 12  months (and up to 5-years) will be per-
formed by recruitment sites via local hospital electronic 
patient records, primary care records and by national 
data-linkage for other NHS databases.
Co-enrolment of patients in existing registries will be 
encouraged (e.g. ISARIC-4c and CAPACITY: Cardiac 
complicAtions in Patients with SARS Corona vIrus 2 
regisTrY; NCT04325412). Also, as this is a longitudi-
nal, observational study, co-enrollment with other UK 
COVID-19 studies/trials will be permitted.
Consent procedures
All recruited patients will provide written informed con-
sent as per the international ethical and scientific quality 
standard of Good Clinical Practice (GCP). Patient infor-
mation sheets for COVID-HEART will be provided in 
English, and also in up to 10 other languages commonly 
spoken in the UK, including: French, Portuguese, Pol-
ish, Urdu, Bengali, Punjabi, Gujarati, Hindi, Somali and 
Arabic.
When eligibility criteria are confirmed, medical staff 
or appropriately trained support staff will seek consent 
from patients after allowing as much time as necessary 
to consider the study, or at least 24 h, whilst the patient 
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is either an in- or out-patient. Consent for participation 
in the coronary vascular sub-study (ethics reference: 
19/EM/0295) will be sought at the time of consent for 
work package-2.
All participants will have the right to withdraw from 
the study at any point. Moreover, the investigator may 
discontinue a participant from the study at any time 
if it is considered necessary for any reason including 
ineligibility, significant protocol deviation or loss to 
follow-up. The reason for withdrawal will be recorded. 
If consent is withdrawn before data are used in any 
research analyses, then data relating to that participant 
could be removed, if the participant explicitly requests 
that their data are not used. In general, if consent is 
withdrawn, or if the patient were to become incapaci-
tated, any data collected up to that point will remain on 
file and will be included in the final study analysis.
Research investigations
All recruited patients will be offered CMR imaging, 
digital 12-lead ECG, validated quality of life ques-
tionnaires, 6  min walk test (6MWT), and additional 
blood sampling for genetic analysis/immunological 
responses/T-cell function and cardiovascular biomark-
ers, if not already acquired. See study flow diagram 
(Fig.  2) and below for detailed description of research 
investigations.
1) CMR Scans will ideally be performed pre-discharge 
or within 28  days of discharge, and then repeated at 
6  months (± 4  weeks) from the date of admission and 
on the same scanner wherever possible. Scans will be 
performed on either a 1.5 T or a 3 T CMR system using 
multi-channel phased-array chest coils of any vendor, 
depending upon local availability. ECG gating will be 
employed for all cardiac gated sequences to ensure appro-
priate triggering. The main CMR protocol is in keeping 
with Society for Cardiovascular Magnetic Resonance 
(SCMR) recommended CMR protocols for scanning 
patients with active or convalescent phase COVID-19 [6], 
and it will take approximately 50 min to acquire, with an 
optional shortened and extended protocol dependent of 
patient preference and ability. An estimated glomerular 
filtration rate (eGFR) and haematocrit will be measured 
prior to each CMR scan. For patients with significant 
renal failure (eGFR < 30 ml/min/1.73  m2), late gadolinium 
enhancement (LGE) and post-contrast T1-mapping can 
be omitted and a contrast-free CMR scan performed.
The main CMR study protocol includes the following 
components and typical parameters, which may vary by 
vendor and field strength, but remain comparable overall 
(Fig. 3):
A. Localiser sequences and breath-hold transverse Half-
Fourier Acquisition Single-shot Turbo spin Echo 
(HASTE) imaging stacks covering lung and abdo-
men to 1–2 cm below the kidneys. Typical sequence 
parameters: TE 1.33 ms, TR 700 ms, slice thickness 
8  mm, FOV = 400  mm, FOV phase 100%, flip angle 
10°.
B. Cine images acquired with breath-hold balanced 
steady-state free precession (bSSFP) sequence. Long-
axis views of the LV: 4-chamber, 2-chamber, and 
3-chamber views. Sequence parameters: TE 1.05 ms, 
TR 40.29 ms, slice thickness 8 mm, 25% distance fac-
tor, FOV = 500 mm, FOV phase 75%, flip angle 50°.
C. Native (pre-contrast) T1-mapping: acquired using a 
single breath-hold shortened modified Look-Locker 
inversion (ShMOLLI) 5(1)1(1)1 technique [31], 
where available. Shimming will be performed to 
avoid artefacts. Native T1-mapping will be acquired 
in 3 short-axis cuts of the LV (basal, mid-ventricular, 
apical) to match the locations of segments 1–16 of 
the American Heart Association 17-segment model 
[32]. The apical segment 17 is omitted. Each acquisi-
tion will be verified against an  R2 map (according to 
vendor availability). Typical pulse sequence param-
eters: TE 1.07 ms, TR 379 ms, slice thickness 8 mm, 
FOV = 360  mm (can be adjusted according to size), 
FOV phase 75%, flip angle 35°, distance factor 25%, 
generalised auto-calibrating partially parallel acquisi-
tion (GRAPPA) 2 with 24 reference lines.
D. Native (pre-contrast) T2-mapping: matching in slice 
location to the T1 maps, will be acquired using either 
a T2-prepped b-SSFP sequence with a minimum of 
3 source images (e.g. MyoMaps T2-mapping for Sie-
mens scanners), or a black-blood prepared, naviga-
tor-gated, free-breathing hybrid gradient (echo pla-
nar imaging, EPI) and spin-echo multi-echo sequence 
(GRASE). Typical sequence parameters: TE 1.3  ms, 
TR 222.43 ms, slice thickness 8 mm, FOV = 360 mm, 
FOV phase 80%, flip angle 20°.
E. Rest myocardial perfusion imaging: obtained using 
pixel-wise perfusion mapping (or locally avail-
able pulse sequence) following administration of 
0.05  mmol/kg of gadolinium based contrast agent 
(GBCA) at 4  ml/s with 20  ml flush at 4  ml/s via a 
power injector. Immediately after rest perfusion 
image acquisition, 0.1  mmol/kg top-up (giving a 
total dose of 0.15 mmol/kg) of GBCA will be given. 
Accepted GBCA agents include: gadobutrol and 
gadoteric acid. Sequence parameters: TE 1.04  ms, 
TR 143.04 ms, slice thickness 8 mm, FOV = 380 mm, 
FOV 75%, flip angle 50°.
F. Ventricular short-axis stack. Sequence parameters 
will match the cine image acquisition in long-axis.
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Fig. 2 Study flow diagram. COVID‑19 patients, who have an elevated troponin, will be invited to participate in the study. Patients who are recruited 
undergo multimodality assessment at index visit: either during their hospital admission or within 28 days of discharge. Assessment includes a 
12‑lead ECG, CMR study, genetic and immunological blood tests, and Quality of Life questionnaires. Patients are subsequently invited for a second 
visit at 6 months. At this point they undergo a repeat CMR scan, quality of life assessments and 6‑min walk test. Further follow up at 12 months will 
be conducted via examination of routine clinical data, available through general practitioners, electronic hospital records, NICOR and NHS Digital, 
and in collaboration with other nationally recognised COVID‑19 studies
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G. Aortic distensibility imaging: planned using bSSFP 
cine sequence of the thoracic aorta in sagittal oblique 
view and then acquired transverse to the ascend-
ing/descending thoracic aorta (at pulmonary artery 
bifurcation level). Blood pressure will be recorded 
whilst in the scanner to allow calculation of aortic 
distensibility. Sequence parameters: TE 1.25 ms, TR 
43.35 ms, slice thickness 6 mm, FOV = 380 mm, FOV 
phase 100%, flip angle 55°, 50 phases.
H. LGE images will be acquired ~ 5–15 min after intra-
venous injection of 0.1–0.15 mmol/kg of GBCA with 
a free-breathing phase-sensitive motion correction 
bSSFP or breath-hold, segmented inversion-recovery 
sequence. Contiguous stack of LV short-axis images 
and single long-axis slices in 2-chamber, 4-chamber 
and 3-chamber at the same slice locations as obtained 
for cine imaging will be acquired. A Look-Locker 
sequence will be used to determine the appropriate 
inversion time (TI) [33]. Example parameters are: TI 
will be adjusted as per Look-Locker sequence, TE 
1.14 ms, TR 411.48 ms, matrix 128 × 256, 8 mm slice 
thickness with 2 mm inter-slice gap, FOV = 400 mm, 
FOV phase 75%, flip angle 47°.
I. Post-contrast T1 measurements will be acquired at the 
exact same locations as the native T1-maps and 
performed at least 10 min after injection of GBCA, 
using the same pulse sequence and parameters as 
the native T1-maps.
J. A subset of patients eligible for coronary vascular 
assessment will undergo an extended protocol at 
baseline to include stress-perfusion imaging. Adeno-
sine stress perfusion imaging will be acquired after 
post-contrast T1 mapping using an adenosine dose 
of 140–210 mcg/kg/min for 3–5  min, whilst moni-
toring symptoms, heart rate and blood pressure to 
assess an adequate response. Subsequently, GBCA 
will be given at a dose of 0.05 mmol/kg at 4 ml/s fol-
lowed by a 20 ml flush at 4 ml/s, giving a total dose 
of 0.2  mmol/kg. Stress perfusion imaging will be 
acquired in the same slice locations as the rest per-
fusion images. Sequence parameters will match the 
resting scan.
2) Digital 12-lead ECG. A 12-lead ECG will be performed 
either as part of routine clinical assessment or as an addi-
tional research test during the index admission and again 
at 6  months follow up. In selected centres (which will 
be provided with an identical study-specific digital ECG 
machine), a full 12-lead digital ECG from COVID-19 
patients will be recorded daily, if possible dependent on 
clinical status, for up to 7 days, whilst an in-patient. Digi-
tal ECGs in patients with CMR-proven myocarditis will 
be compared to a reference dataset of acute ST-elevation 
myocardial infarction patients already available from the 
0 Time 
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Fig. 3 COVID‑HEART study CMR protocol. The full protocol takes approximately an hour, and comprises (in order of acquisition): localisers and axial 
HASTE stack, cine images of the left ventricle in long‑axis views, pre‑contrast T1 mapping and T2 mapping, rest myocardial perfusion after injection 
of 0.05 mmol/kg of gadolinium based contrast agent (GBCA) followed immediately with 0.1 mmol/kg top‑up (giving a total dose of 0.15 mmol/
kg). Then a ventricular short‑axis stack and aortic cine images (aortic distensibility, followed by late gadolinium enhancement (LGE) imaging and 
post‑contrast T1 mapping. The last component (dependent on patient suitability) is stress perfusion imaging, performed after administration of 
adenosine stress at dose of 140‑210mcg/kg/min, utilising a further 0.05 mmol/kg of GBCA
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NIHR-Efficacy and Mechanism Evaluation Programme 
funded T-TIME randomised controlled trial [34].
3) Functional assessment by 6-min walk test. Participants 
will asked to perform a standard 6MWT at the 6-month 
visit following the American Thoracic Society guidelines 
[35]. Patients will be instructed to walk along a corridor 
and turn at 15 m in order to cover the maximum distance 
in 6 min under the supervision of study investigators. The 
investigators will tell the participant how much time had 
elapsed every 2 min and encourage participants to con-
tinue at intervals of between 30 s and 1 min. At the end of 
6 min, participants will be asked to stop, and the distance 
walked will be measured in metres.
4) Quality of life questionnaires. All participants will be 
asked to complete patient-reported health status ques-
tionnaires (36-Item Short Form Health Survey; SF-36v2) 
and a health-related QoL questionnaire (EQ-5D-5L) at 
baseline and 6  months. These will be performed either 
face to face, by telephone or by post, depending on local 
site and individual patient circumstances and prefer-
ences. These questionnaires were chosen to align with 
other UK national COVID-19 research studies (e.g. 
C-MORE/P-HOSP-COVID).
5) Laboratory investigations. As part of clinical routine, 
patients will undergo routine laboratory testing, includ-
ing full blood count, renal and liver profile, inflammatory 
markers, and cardiovascular biomarkers (e.g. troponin 
and brain natriuretic peptide (BNP)). Additional research 
blood sampling for genetic analysis/inflammatory mark-
ers will be performed, if not already acquired from par-
ticipation in other UK COVID-19 research studies. 10 ml 
of blood will be drawn into an ethylenediaminetetraacetic 
acid (EDTA) bottle. The tube will be inverted 5 times and 
transferred on ice. The sample will be centrifuged for 
20 min at 2000G at 4 °C. The sample will be divided into 
6 × 1  ml Thermo Matrix tubes. Subsequently a pipette 
will be used to provide 5 aliquots. Plasma will be taken 
from the centre of each sample avoiding the buffy coat 
layer, which will be retained separately. Samples will be 
labelled with a unique study ID and stored locally on-site, 
pending batch transfer for analysis at Leicester University 
and the University of Glasgow.
Follow‑up
Patients will be followed up at 6 months (± 4 weeks) from 
date of the diagnosis of COVID-19, and invited to have a 
second CMR scan, ECG, QoL assessment (SF-36v2 and 
EQ-5D-5L) and functional assessment (6MWT). In addi-
tion, routine clinical outcome data will be collated up to 
5  years post-infection from: electronic patient records, 
general practice information systems, National Institute 
for Cardiovascular Outcomes Research (NICOR) and 
NHS Digital (eDRIS in Scotland).
Study outcomes
Main outcomes
1) Presence, extent, distribution of LGE
2) CMR biventricular volumes and function
3) Functional capacity (6MWT) and QoL measures
4) Long-term clinical outcomes
Exploratory outcomes
1) CMR: T1, T2 mapping indices, myocardial strain, 
myocardial perfusion, aortic distensibility measures.
2) ECG indices
3) Biomarker and genetic analyses
4) Coronary atheroma extent (coronary vascular sub-
study)
Analysis plan
The prevalence and extent of cardiac involvement in 
patients with COVID-19 and raised troponin will be 
described by CMR. Predictors of cardiac dysfunction and 
recovery such as: blood biomarkers, the severity of the 
acute infection, genetics, and comorbidities will be iden-
tified. The determinants of adverse clinical outcome in 
this population will also be examined. Outcome assess-
ments (clinical event adjudication) will be undertaken at 
individual hospital sites according a pre-specified stand-
ard definition set (Appendix  1) contained with a signed 
clinical outcome charter.
1) CMR data: All quantitative analyses will be performed 
blinded to participant status. CMR data sets will be ana-
lysed by a disseminated core-lab technique as previously 
used in the BSCMR UK valve consortium [36]. LV struc-
ture and function including mass and wall thickness will 
be analyzed using a clinically validated artificial intel-
ligence (AI) analysis platform [37]. Left atrial area and 
global longitudinal shortening will be similarly analyzed 
by further validated artificial intelligence approaches 
[38]. LGE patterns will also be classified into patterns 
reflecting likely aetiology and quantitative assessment 
will be performed by semi-automated signal intensity 
analysis according to the full width at half maximum 
technique and other thresholds where appropriate [36]. 
Evidence of pericarditis will be assessed on cine, LGE 
and tissue characterisation images. T1 and T2 mapping 
will be quality-assured and analysed to establish the 
Page 9 of 13Gorecka et al. J Cardiovasc Magn Reson           (2021) 23:77  
global and segmental T1 and T2 values, using stand-
ardised approaches developed by the Oxford group [39, 
40]. Myocardial perfusion assessment for the coronary 
vascular sub-study will be carried out by segmental and 
global quantitative myocardial blood flow calculation 
during rest and adenosine stress; it will be calculated 
from fully automated in-line quantification [41, 42]. In 
addition, visual perfusion defects will be scored semi-
quantitatively by 2 observers as previously described [43] 
with disagreement resolved by a third reader. The likeli-
hood of microvascular disease (patchy perfusion defects 
not following the distribution of a coronary distribution 
or circumferential defects not affecting apical segments) 
will be recorded. Circumferential strain and strain rates 
will be generated by automated tissue tracking software 
(cvi42, Circle Cardiovascular Imaging,  Alberta, Calgary, 
Canada) as previously described [44]. Aortic distensibil-
ity will be assessed using blood pressure assessments and 
measurements of the cross-sectional area of the ascend-
ing aorta in systole and diastole on axial cine slices at the 
level of the right pulmonary artery. Distensibility = (aor-
tic max lumen area − aortic min lumen area)/(aortic min 
lumen area * [systolic blood pressure − diastolic blood 
pressure]).
2) ECG data: The standard and digital 12-lead ECGs will 
be electronically transferred via the study portal into the 
image repository at the coordinating centre in Glasgow, 
Scotland. Digital ECGs will be analysed in the University 
of Glasgow ECG core lab utilising the previously vali-
dated Glasgow ECG analysis software [45]. A full set of 
measurements plus interpretation will be extracted for 
analysis of ECG changes and statistical processing, with 
the aim of determining sensitive and specific criteria for 
diagnosing myocarditis from the ECG, and prognostic 
ECG findings in this population [46]. ECGs available in 
printed form will also be electronically transmitted in 
pdf format to the ECG Core Lab for standardised review 
based on the same criteria as used in the Glasgow pro-
gram. Manually classified changes will also be subject to 
statistical analysis.
3) Laboratory data: All blood samples will be transferred 
to the central coordinating centre in Leicester, England 
and analysed in the University of Leicester Cardiovascu-
lar Research Centre and the BHF Glasgow Cardiovascu-
lar Research Centre, University of Glasgow. Analysis will 
entail novel cardiovascular biomarkers (e.g. vascular cell 
adhesion molecule, interleukin-6) and markers of genetic 
susceptibility to COVID-19. The genetic analysis will be 
used to explore links specifically in the black and minor-
ity ethnic populations and linked in with existing cohorts 
for genotyping (The Genetics and Vascular Health Check 
study, The Biomedical Research Informatics Centre for 
Cardiovascular Science and UK Biobank).
4) 6MWT: As per the American Thoracic Society guide-
lines, the distance walked (measured in meters) in 6 min 
will be recorded by the investigator supervising the test. 
Symptoms of perceived breathlessness will be recorded 
on the Borg scale and if the test was stopped early, the 
reason will be recorded.
5) Quality of life questionnaires: Patients’ responses to the 
36-Item Short Form Health Survey and the health-related 
QoL questionnaire (EQ-5D-5L) will be recorded in the 
eCRF by the investigators. Each of the 8 health domains 
measured by the SF-36v2 will be given a combined per-
centage score, with higher percentage scores represent-
ing a better level of functioning. Each of the 5 domains 
of the EQ-5D-5L will be scored on a 1–5 scale, with level 
1 indicating no problems with a particular domain and 
level 5 indicating extreme problems. Health state of an 
individual patient will be determined by combining the 
levels from all the domains.
Statistical considerations
Sample size considerations
Patients in work package-1 will originate from the open 
national image repository for all UK CMR centres, and 
therefore no sample size calculation is required. For 
work package-2, based on the assumption that the mean 
prevalence of myocardial involvement was 12% (mid-
range) from previous studies, a precision of 3.5% and 95% 
confidence level, a sample size of 333 ± 3.5% would be 
required. To account for a 10% drop out rate, it was cal-
culated that 370 patients are needed.
Statistical analysis
Statistical analyses will be conducted after production of 
a signed statistical analysis plan and once baseline and 
follow-up data collection has been completed. Broadly, 
the statistical methods for each study objective will be as 
follows:
1) to characterise the nature and extent of myocardial 
involvement in COVID-19 patients with an ele-
vated troponin, analyses will be descriptive, and will 
involve estimation of prevalence with 95% confidence 
intervals (CIs);
2) to assess how cardiac involvement and clinical out-
comes associate with recognised risk factors for mor-
tality in COVID-19 (age, sex, ethnicity and comor-
bidities) and with genetic factors, we shall present 
tabular and graphical descriptive summaries within 
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subgroups, and use logistic regression to test for 
associations and provide estimates with 95% CIs;
3) to evaluate if differences in myocardial recovery at 
6  months are associated with demographics, genet-
ics and CV comorbidities (diabetes, hypertension, 
heart failure and CAD/peripheral vascular disease), 
descriptive summaries, and linear and logistic regres-
sion methods will be applied;
4) to understand the association between recovery 
status at 6  months and patient-reported QoL and 
functional capacity, descriptive methods, and linear 
regression will be used.
To assess whether there are characteristic ECG findings 
specific for SARS-CoV-2 myocarditis, measures of diag-
nostic performance will be calculated, and ROC analyses 
will be used.
In the coronary vascular sub-study, descriptive meth-
ods will be used to establish the nature and prevalence 
of myocardial ischaemia and microvascular dysfunction, 
and linear regression methods, including mixed effects 
methods for modelling myocardial blood flow within seg-
ments 1–16 of the American Heart Association 17-seg-
ment model, will be used to assess risk factors.
Throughout these analyses, levels of missing data will 
be reported, and regression models will be fitted using 
multiple imputation of missing predictor variables. 
Where appropriate, data from other cohorts will be used 
as control populations.
Data monitoring and linkage
The University of Glasgow will be coordinating centre 
for data and analysis and will hold identifiable data in 
secured databases to permit record linkage. The Uni-
versities of Leicester and Glasgow and NHS Laboratory 
Medicine (including the Biorepository) will undertake 
storage and/or analysis of blood samples (DNA, RNA, 
and small molecules).
As part of the patient consent process, it will be explic-
itly requested that anonymised data and images can be 
shared with other national and global research initiatives, 
for efficiency in data collection and sharing across other 
nationally prioritised UK COVID studies (e.g. C-MORE, 
P-HOSP-COVID and CISCO-19 [Cardiovascular and 
Pulmonary Imaging in SARS Coronavirus disease-19]) 
[47], as well as with other international CMR studies and 
registries e.g. the international SCMR COVID-19 regis-
try. The principles set out in the 2016 Statement on data 
sharing in public health emergencies will be followed and 
it will be ensured that the World Health Organization 
(WHO) has rapid access to the emerging findings that 
could aid the global response.
As this is an observational study only serious adverse 
events (SAEs) that relate directly to the participation 
in the study procedures and sample collection will be 
reported to the sponsor and Ethics committee. All hospi-
talisations and deaths will be recorded as study outcomes.
The management of incidental findings of the research 
CMR scans will be performed at the individual site level 
according to the normal local practice and procedures.
Discussion
The COVID-HEART study is a longitudinal, multicen-
tre, observational cohort study of UK patients presenting 
with COVID-19 infection and positive troponin, who are 
either recovering in hospital or were recently discharged. 
It aims to utilise CMR in evaluation of the nature and 
extent of myocardial injury and subsequently, myocardial 
recovery in these patients, and to examine the impact of 
myocardial recovery status on quality of life and func-
tional capacity. Additional investigations include labora-
tory testing, which will encompass routine tests, novel 
cardiac biomarkers, and genetic analysis. These results 
will be shared with other global initiatives to address 
genetic susceptibility to COVID-19. Furthermore, ECGs 
will be investigated with the aim of identifying sensitive 
and specific changes that would allow diagnosis of myo-
carditis without the need for invasive testing.
As COVID-19 is an unprecedented global health 
emergency and previous studies showed that a signifi-
cant proportion of patients had myocardial injury, it is 
important to further understand the underlying patho-
physiology, risk factors and long-term outcomes. There-
fore, the results of the COVID-HEART study, and the 
results of other registries examining myocardial injury 
(e.g. PHOSP-COVID, ISRCTN10980107; MOIST, 
NCT04525404; MYOCOVID, NCT04375748; MIIC-MI, 
NCT04412369; CARDOVID, NCT04455347; CISCO-
19, NCT04403607), may have significant clinical impli-
cations on the assessment and management of these 
patients. Furthermore, the new knowledge from these 
studies will help inform disease-targeted therapy devel-
opment, for the prevention and treatment of cardiovas-
cular complications in COVID-19.
Appendix 1: Summary definitions of clinical 
outcomes
A pre-specified, signed, Clinical Outcomes Charter will 
be provided to each recruitment centre. This will contain 
detailed endpoint definitions to facilitate consistent local 
adjudication and unbiased reporting. Endpoint defini-
tions will align with the 2014 American College of Car-
diology/American Heart Association Key Data Elements 
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and Definitions for Cardiovascular Endpoint Events in 
Clinical Trials [48]. In brief, these endpoints will include:
1) Cardiovascular death is a defined as death occurring 
secondary to an acute myocardial infarction, sudden 
cardiac death, heart failure, stroke, death resulting 
from cardiovascular procedures or death due to car-
diovascular haemorrhage.
2) Non-cardiovascular death is defined as any death 
with a specific cause that is not thought to be due to 
a cardiovascular cause. There should be unequivocal 
and documented evidence of a non-cardiovascular 
cause of death.
3) Myocardial infarction is defined as elevation of car-
diac biomarkers above the 99th percentile of the 
upper reference limit in the setting of an appropriate 
clinical presentation in combination with diagnos-
tic ischaemic electrocardiographic changes. Specific 
clinical classification of different types of myocardial 
infarction will be assigned from the 4th Universal 
Definition of Myocardial Infarction [12].
4) Coronary artery revascularisation, either by percuta-
neous coronary intervention (PCI) or coronary artery 
bypass graft surgery (CABG).
5) Transient ischaemic attack is defined as an episode of 
focal neurological dysfunction resulting from brain, 
retinal and spinal cord ischaemia, that is transient in 
nature and resolves within 24 h.
6) Stroke is defined as a focal or global neurological dys-
function secondary to brain, retinal or spinal cord 
injury resulting from haemorrhage or infarction.
7) Pulmonary embolism is defined based upon clini-
cal evaluation and a diagnostic imaging test, ideally, 
computed tomography (CT) pulmonary angiography. 
If ventilation/perfusion scintigraphy is used, then the 
diagnosis may be accepted based on clinical evalua-
tion and a high probability scan. The clinical evalu-
ation and diagnosis of pulmonary embolism should 
align with the 2019 ESC Guidelines for the diagnosis 
and management of acute pulmonary embolism [49].
8) Deep venous thrombosis (DVT) diagnosis should be 
established based on a clinical evaluation, D-dimer 
elevation and imaging findings (duplex ultrasound or 
CT angiography).
9) Myopericarditis diagnosis will be adjudicated based 
upon the 2013 Position Statement of the European 
Society of Cardiology Working Group on Myocardial 
and Pericardial Diseases.(50)
10) Hospitalisation for other cardiovascular cause:
a) Heart failure events are defined as hospitalisation 
for heart failure or an urgent outpatient visit. A 
heart failure hospitalisation event must fulfil the 
following criteria: primary admission diagnosis is 
heart failure, the patient experiences either wors-
ening of heart failure symptoms or a new symp-
tom, and requires an increase in therapy.
b) Arrhythmia defined as hospitalisation with an 
arrhythmia (atrial, supraventricular and/or ven-
tricular or brady-arrhythmia) documented by 
electrocardiography (single- or multi-lead) with a 
change in treatment (withhold, change in dose of 
existing medication, prescription of new medica-
tion for arrhythmia) and/or pacemaker therapy.
c) Chest pain/unstable angina defined as an emer-
gency/unplanned admission to a hospital setting 
that results in at least one overnight stay (i.e. a 
date change) with cardiac ischaemic-type symp-
toms at rest or minimal exertion.
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